IN SILICO VACCINE DESIGN AGAINST THE TARGET L1 BINDING PROTEIN OF HUMAN PAPILLOMAVIRUS, AN ETIOLOGICAL AGENT OF CERVICAL CANCER, USING BIOINFORMATICS TOOLS

被引:3
|
作者
Kaushik, Shuchi [1 ]
Shrivastav, Vivek Kumar [2 ]
Shrivastav, Archana [2 ]
Jana, Asha Mukul [1 ]
机构
[1] Canc Hosp & Res Inst Campus, Coll Life Sci, Dept Biotechnol, Gwalior 474009, Madhya Pradesh, India
[2] Canc Hosp & Res Inst Campus, Coll Life Sci, Dept Microbiol, Gwalior 474009, Madhya Pradesh, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2013年 / 4卷 / 12期
关键词
HPV; Tumors; Immune-informatics; Vaccine;
D O I
10.13040/IJPSR.0975-8232.4(12).4758-62
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human Papilloma Virus (HPV) is the smallest virus in the world. HPV is a non-enveloped double-stranded circular DNA virus, which can widely infect human skin and reproductive tract and respiratory epithelium. HPV also has a close relationship with benign and malignant tumors. There is no universal HPV treatment. Although there is a vaccine called Gardasil that can prevent some diseases caused by HPV, it is not recommended for everyone and does not eliminate the chance of getting other types of HPV. Thus, the aim of the present study is to design a subunit vaccine against HPV using bioinformatics approaches. In order to achieve our objective, we have used B-cell and T-cell epitope prediction methods. The possible vaccine target was proposed by using the conserved sequence among the chosen L1 binding protein from twenty different sequences. Structure prediction of this sequence by PSIPRED revealed that one helix is present in the sequence. The use of immune-informatics has greatly revolutionized the field of vaccine research, discovery and development. It demands the proper computational investigations of every possible antigenic candidate. The present study finds that L141 protein of HPV can be also an effective candidate for the development of preventive measures against the drastic diseases caused by the virus by blocking its resistance efficiency. In fact in silico approach for vaccine target prediction are definitely reducing manpower, time and cost in relation to searching a lead antigenic molecule against the L1 protein.
引用
收藏
页码:4764 / 4768
页数:5
相关论文
共 27 条
  • [1] In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer
    Gupta, Shishir Kumar
    Singh, Archana
    Srivastava, Mugdha
    Gupta, Shailendra K.
    Akhoon, Bashir Akhlaq
    VACCINE, 2009, 28 (01) : 120 - 131
  • [2] Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine
    Luxembourg, Alain
    Bautista, Oliver
    Moeller, Erin
    Ritter, Michael
    Chen, Joshua
    CONTEMPORARY CLINICAL TRIALS, 2015, 42 : 18 - 25
  • [3] In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design
    Hosseini, Nazila Ghorban
    Tebianian, Majid
    Farhadi, Ayoub
    Khani, Ali Hossein
    Rahimi, Arian
    Mortazavi, Mojtaba
    Hosseini, Seyed Younes
    Taghizadeh, Morteza
    Rezaei, Mahsa
    Mahdavi, Mehdi
    VIRAL IMMUNOLOGY, 2017, 30 (03) : 210 - 223
  • [4] The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein
    Behzad Dehghani
    Zahra Hasanshahi
    Tayebeh Hashempour
    Mohamad Motamedifar
    Biologia, 2020, 75 : 749 - 759
  • [5] The possible regions to design Human Papilloma Viruses vaccine in Iranian L1 protein
    Dehghani, Behzad
    Hasanshahi, Zahra
    Hashempour, Tayebeh
    Motamedifar, Mohamad
    BIOLOGIA, 2020, 75 (05) : 749 - 759
  • [6] In silico analysis of HLA-1 and HLA-2 recognition of a designed recombinant human papillomavirus vaccine based on L1 protein HPV subtype 45
    Sulfianti, Asri
    Karimah, Nihayatul
    Nurhasanah, Astutiati
    JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, 2023, 21 (01)
  • [7] In silico analysis of HLA-1 and HLA-2 recognition of a designed recombinant human papillomavirus vaccine based on L1 protein HPV subtype 45
    Asri Sulfianti
    Nihayatul Karimah
    Astutiati Nurhasanah
    Journal of Genetic Engineering and Biotechnology, 21
  • [8] Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein
    Wang, Yan
    Shang, Qinglong
    Xu, Weizhen
    Li, Di
    Gu, Hongxi
    Wei, Lanlan
    DIAGNOSTIC PATHOLOGY, 2014, 9
  • [9] Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer
    Ryan, Nicholas
    Pratiwi, Sari Eka
    Mardhia, Mardhia
    Ysrafil, Ysrafil
    Liana, Delima Fajar
    Mahyarudin, Mahyarudin
    OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES, 2024, 15 (04) : 307 - 328
  • [10] Genetic diversity in L1 ORF of human papillomavirus in women with cervical cancer with and without human immunodeficiency virus in Botswana and Kenya
    Tawe, Leabaneng
    Choga, Wonderful T.
    Paganotti, Giacomo M.
    Bareng, Ontlametse T.
    Ntereke, Tlhalefo D.
    Ramatlho, Pleasure
    Ditshwanelo, Doreen
    Gaseitsiwe, Simani
    Kasvosve, Ishmael
    Ramogola-Masire, Doreen
    Orang'o, Omenge E.
    Robertson, Erle
    Zetola, Nicola
    Moyo, Sikhulile
    Grover, Surbhi
    Ermel, Aaron C.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)